To investigate whether expression of mutant KRAS is required for PIERCE1-mediated increase of pAKT, its level was monitored in the KRAS WT and non-tumor cell lines under PIERCE1 and/or mutant KRAS overexpressed conditions. This evidence concerns the gene KRAS and neoplasm.